Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 09, 2026 08:05 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference

Following Guidance from the European Medicines Agency’s (EMA) Scientific Advice Working Party (SAWP) Regarding Iopofosine I 131 for the Treatment of Waldenstrom’s Macroglobulinemia (WM), Expects to...
January 09, 2026 08:05 ET | Source: GigaCloud Technology

GigaCloud Technology Inc to Participate in 28th Annual Needham Growth Conference

EL MONTE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B technology solutions for large parcel...
January 09, 2026 08:04 ET | Source: Cartesian Therapeutics, Inc.

Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook

Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential...
January 09, 2026 08:00 ET | Source: Hurco Companies, Inc.

Hurco Reports Fourth Quarter and Full Year Results for Fiscal Year 2025

INDIANAPOLIS, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Hurco Companies, Inc. (Nasdaq: HURC) today reported results for the fourth fiscal quarter and fiscal year ended October 31, 2025. Hurco recorded a net...
January 09, 2026 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones

-- Q4 2025 preliminary net product revenues from global sales of IMCIVREE® (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an 11% increase over Q3 2025 -- -- FY 2025...
January 09, 2026 08:00 ET | Source: American Rebel Holdings Inc

American Rebel Board and Executive Leadership Convert Approximately $2.05 Million of Accrued Fees and Compensation into Equity, Further Strengthening Stockholders’ Equity and Reducing Accrued Liabilities

Board of Directors, senior management (including the President and Chief Executive Officer) and former President elect to convert accrued obligations into Series D Convertible Preferred Stock; action...
January 09, 2026 08:00 ET | Source: Silicon Motion Technology Corporation

Silicon Motion Announces Fourth Quarter 2025 Earnings Conference Call

TAIPEI, Taiwan and MILPITAS, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Silicon Motion Technology Corporation (NasdaqGS: SIMO) (“Silicon Motion” or the “Company”), a global leader in NAND flash...
January 09, 2026 08:00 ET | Source: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities

-- EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26 -- -- Phase 3 PREVAIL CVOT overall event rate tracking in line with observed rate in BROADWAY -- ...
January 09, 2026 08:00 ET | Source: Rigetti Computing, Inc.

Rigetti Computing Provides Update on 108-Qubit System

Rigetti Computing Provides Update on 108-Qubit System
January 09, 2026 08:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor

Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapiesDGAT-2 inhibition represents a complementary mechanism of action with Rezdiffra® (resmetirom) for...